Literature DB >> 9584261

Varicella and varicella immunity in patients with lysinuric protein intolerance.

M Lukkarinen1, K Näntö-Salonen, O Ruuskanen, T Lauteala, S Säkö, M Nuutinen, O Simell.   

Abstract

Two patients with lysinuric protein intolerance (LPI) had near-fatal generalized varicella infection with severe interstitial pneumonitis, hepatitis, decreased platelet count, bleeding and hypoalbuminaemia. Active haemolysis resulted in anaemia and massive haemoglobinuria. Serum lactate dehydrogenase activity and ferritin concentration, which in patients with LPI in normal circumstances exceed the upper reference values 3-folds to 10-fold, increased to > 10,000 U/L and > 10,000 micrograms/L, respectively. The patients were treated with fresh frozen plasma, red-cell transfusions and intravenous acyclovir for 14 days, and recovered clinically in a month. Retrospectively, 3 of the 32 other known Finnish patients with LPI had had varicella infection that had been more severe than that in the other children in the family or in subjects in the neighbourhood and had led to hospital admission. Varicella antibodies were measured in 24 patients; 5 had no antibodies and 5 had very low antibody titres. Primary vaccination of three patients with living varicella vaccine increased antibody titres measurably in one patient. We suggest that patients with LPI who have no varicella zoster antibodies should be treated with acyclovir if exposed to varicella and should be (re)vaccinated against chickenpox.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9584261     DOI: 10.1023/a:1005335423939

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  12 in total

1.  A randomized, controlled trial of vitamin A in children with severe measles.

Authors:  G D Hussey; M Klein
Journal:  N Engl J Med       Date:  1990-07-19       Impact factor: 91.245

2.  Lysinuric protein intolerance.

Authors:  J Rajantie; J Perheentupa
Journal:  Lancet       Date:  1980-11-01       Impact factor: 79.321

3.  Protein intolerance with deficient transport of basic aminoacids. Another inborn error of metabolism.

Authors:  J Perheentupa; J K Visakorpi
Journal:  Lancet       Date:  1965-10-23       Impact factor: 79.321

4.  Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis.

Authors:  R S Griffith; D E Walsh; K H Myrmel; R W Thompson; A Behforooz
Journal:  Dermatologica       Date:  1987

5.  Reduced mortality among children in southern India receiving a small weekly dose of vitamin A.

Authors:  L Rahmathullah; B A Underwood; R D Thulasiraj; R C Milton; K Ramaswamy; R Rahmathullah; G Babu
Journal:  N Engl J Med       Date:  1990-10-04       Impact factor: 91.245

6.  Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group.

Authors:  A A Gershon; S P Steinberg
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

7.  Lysinuric protein intolerance.

Authors:  O Simell; J Perheentupa; J Rapola; J K Visakorpi; L E Eskelin
Journal:  Am J Med       Date:  1975-08       Impact factor: 4.965

8.  Postexposure prophylaxis of varicella in family contact by oral acyclovir.

Authors:  Y Asano; T Yoshikawa; S Suga; I Kobayashi; T Nakashima; T Yazaki; T Ozaki; A Yamada; J Imanishi
Journal:  Pediatrics       Date:  1993-08       Impact factor: 7.124

9.  Acyclovir treatment of disseminated varicella in childhood malignant neoplasms.

Authors:  S T Shulman
Journal:  Am J Dis Child       Date:  1985-02

10.  Vitamin A supplementation and child mortality. A meta-analysis.

Authors:  W W Fawzi; T C Chalmers; M G Herrera; F Mosteller
Journal:  JAMA       Date:  1993-02-17       Impact factor: 56.272

View more
  8 in total

1.  B and T cell immunity in patients with lysinuric protein intolerance.

Authors:  M Lukkarinen; K Parto; O Ruuskanen; O Vainio; H Käyhty; R M Olander; O Simell
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

Review 2.  Overview of symptoms and treatment for lysinuric protein intolerance.

Authors:  Atsuko Noguchi; Tsutomu Takahashi
Journal:  J Hum Genet       Date:  2019-06-18       Impact factor: 3.172

Review 3.  Inborn errors of metabolism underlying primary immunodeficiencies.

Authors:  Nima Parvaneh; Pierre Quartier; Parastoo Rostami; Jean-Laurent Casanova; Pascale de Lonlay
Journal:  J Clin Immunol       Date:  2014-08-01       Impact factor: 8.317

4.  Toxic effect of acyclovir on testicular tissue in rats.

Authors:  Elham Movahed; Vahid Nejati; Rajabali Sadrkhanlou; Abbas Ahmadi
Journal:  Iran J Reprod Med       Date:  2013-02

5.  Lysinuric protein intolerance in a family of Mexican ancestry with a novel SLC7A7 gene deletion. Case report and review of the literature.

Authors:  David Carpentieri; Margaret F Barnhart; Kyrieckos Aleck; Tamir Miloh; Daphne deMello
Journal:  Mol Genet Metab Rep       Date:  2015-01-10

Review 6.  Amino Acid Transport Defects in Human Inherited Metabolic Disorders.

Authors:  Raquel Yahyaoui; Javier Pérez-Frías
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

7.  Immune Dysregulation Mimicking Systemic Lupus Erythematosus in a Patient With Lysinuric Protein Intolerance: Case Report and Review of the Literature.

Authors:  Josefina Longeri Contreras; Mabel A Ladino; Katherine Aránguiz; Gonzalo P Mendez; Zeynep Coban-Akdemir; Bo Yuan; Richard A Gibbs; Lindsay C Burrage; James R Lupski; Ivan K Chinn; Tiphanie P Vogel; Jordan S Orange; M Cecilia Poli
Journal:  Front Pediatr       Date:  2021-05-20       Impact factor: 3.418

8.  Inducible Slc7a7 Knockout Mouse Model Recapitulates Lysinuric Protein Intolerance Disease.

Authors:  Susanna Bodoy; Fernando Sotillo; Meritxell Espino-Guarch; Maria Pia Sperandeo; Aida Ormazabal; Antonio Zorzano; Gianfranco Sebastio; Rafael Artuch; Manuel Palacín
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.